 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (September 2017) |
Autologous matrix-induced chondrogenesis (AMIC) is a treatment for articular cartilage damage. It combines microfracture surgery with the application of a bi-layer collagen I/III membrane. There is tentative short to medium term benefits as of 2017.[1]
The initialism AMIC, often used as a genericized trademark, is a registered trademark of Ed. Geistlich Söhne AG, protected by German Registration No. 30255356 [2] and international Registration No. 840373.[3]
- ^ Shaikh, N; Seah, MKT; Khan, WS (18 July 2017). "Systematic review on the use of autologous matrix-induced chondrogenesis for the repair of articular cartilage defects in patients". World Journal of Orthopedics. 8 (7): 588–601. doi:10.5312/wjo.v8.i7.588. PMC 5534408. PMID 28808630.
- ^ "Deutsche Patent- und Markenamt (DPMA), registration # 30255356". 2002-11-11. Retrieved 2013-01-25.
- ^ "World Intellectual Property Organization (WIPO), registration # 840373". 2004-08-18. Retrieved 2013-01-25.